Advanced Enzyme buyback: ₹69.7 cr open-market plan 2026

Key decisions from the August 8 board meeting

Advanced Enzyme Technologies Limited said its Board of Directors, at a meeting held on August 08, 2026, approved a share buyback, a minority stake acquisition in a subsidiary, additional funding for a wholly owned subsidiary, and the company’s unaudited Q1 financial results. The buyback is proposed through the stock exchange mechanism using the open market route. Alongside the capital return proposal, the board cleared a deal to acquire the remaining minority stake in JC Biotech Private Limited (JCB). It also approved a further fund infusion into Advanced Nutrazyme Private Limited (ANPL). The company also reiterated compliance steps around insider trading controls, including a trading window closure around results.

Share buyback: size, price cap, and route

The board approved a buyback of fully paid-up equity shares with a face value of ₹2 each at a price not exceeding ₹500 per share. The aggregate buyback size will not exceed ₹697.00 million. At the maximum price and maximum size, the indicative maximum number of shares to be bought back is 1,394,000 equity shares. The company said this represents 1.24% of the existing paid-up equity capital. The buyback will be payable in cash.

Who can participate in the buyback

Advanced Enzyme said the buyback will be conducted from shareholders other than Promoters, the Promoter Group, and Persons in Control of the company. The transaction will be executed via the “Open Market” route through the stock exchange mechanism. The company said the buyback will be carried out in accordance with the SEBI (Buy-Back of Securities) Regulations, 2018 and the Companies Act, 2013. It also stated that a public announcement, including process and timelines, will be released in due course.

Buyback limits referenced to audited reserves

The company disclosed how the buyback size compares with capital and reserves based on the latest audited financial statements as on March 31, 2026. It said the maximum buyback size represents 9.99% of the aggregate of total paid-up equity share capital and free reserves on a standalone basis. On a consolidated basis, the same buyback size represents 5.09% of the aggregate of total paid-up equity share capital and free reserves. These disclosures matter because buyback regulations tie permissible limits to audited capital and reserves.

Buyback committee and next disclosures

The board constituted a Buyback Committee and delegated powers to it for the buyback process. The company said the committee will handle actions needed to implement the board’s decision, within the relevant regulatory framework. A public announcement is expected to set out the detailed process, timelines, and other statutory disclosures. Until that is released, investors will not have the full sequence of steps that typically covers broker appointment, buyback period, and reporting requirements.

Pre and post buyback shareholding snapshot

The company provided a pre and post buyback shareholding pattern assuming repurchase of the maximum 1,394,000 shares at ₹500 per share. Under this illustration, promoter holdings remain unchanged in number of shares, while public shareholding reduces due to share extinguishment. As a result, the promoter percentage rises even though promoter shares are not bought back.

JC Biotech: remaining 4.28% to be acquired

The board approved the acquisition of the remaining 4.28% equity stake in JC Biotech Private Limited. The company said it will buy 886,544 equity shares from other existing shareholders at ₹90 per share, for a total consideration of ₹79.79 million. Advanced Enzyme currently holds 95.72% in JCB, and the transaction will raise this to 100%, making JCB a wholly owned subsidiary upon completion. The indicative timeline for completion is September 30, 2026.

Advanced Nutrazyme: additional infusion up to ₹20 million

The board also approved an additional fund infusion into Advanced Nutrazyme Private Limited, a wholly owned subsidiary. The company said the infusion will not exceed ₹20.00 million and may be made in one or more tranches. It may be structured as an equity investment or as an inter-corporate deposit. The indicative timeline for completion is December 31, 2027.

Q1 results: consolidated and standalone performance (June 30, 2026)

On a consolidated basis, Advanced Enzyme reported revenue from operations of ₹1,897.88 million for the quarter ended June 30, 2026. Consolidated net profit for the quarter was ₹385.89 million. On a standalone basis, revenue from operations stood at ₹1,158.57 million and net profit was ₹223.46 million for the same quarter. The company said the board approved the unaudited standalone and consolidated financial results for this period.

Dividend and record-date context

Separately, the company’s board had proposed a final dividend of ₹1.35 per equity share for FY 2025-26. This dividend was approved by shareholders at the Annual General Meeting held on July 31, 2026. The company said the dividend was paid on August 5, 2026. It had also announced July 24, 2026 as the record date to determine shareholder eligibility for this final dividend.

Market impact: stock move and trading window closure

The shares of Advanced Enzyme Technologies closed lower by 1.79% or ₹5.90, as cited in the disclosure summary, taking the price to ₹323.90 per share. The company also noted that the stock price has risen 11.08% over the past six months. In addition, the company stated that the trading window for dealing in its securities remained closed until August 10, 2026, following an earlier intimation dated June 25, 2026, in line with insider trading prevention norms. Such trading window restrictions are standard around price-sensitive announcements like quarterly results and buybacks.

Analysis: why the combination of actions matters

The buyback decision, if executed up to the stated maximum, reduces the outstanding share count in the company’s illustrated post-buyback table and changes ownership percentages mechanically. The company’s choice of the open market route and the explicit exclusion of promoters and persons in control sets the eligible participation pool to non-promoter shareholders. The acquisition of the remaining stake in JCB and the planned infusion into ANPL indicate continued capital allocation toward subsidiaries alongside capital return to shareholders. The disclosed Q1 numbers provide the near-term earnings context that often frames buyback discussions, though the company has not linked the buyback to any specific valuation or earnings objective in the material provided.

Conclusion

Advanced Enzyme’s August 08, 2026 board meeting cleared a ₹697.00 million share buyback at up to ₹500 per share via the open market route, alongside steps to make JC Biotech a wholly owned subsidiary and to infuse up to ₹20.00 million into Advanced Nutrazyme. The company also approved unaudited Q1 results for the quarter ended June 30, 2026 on both consolidated and standalone bases. The next key update expected is the public announcement detailing the buyback process and timelines, while the company’s stated trading window closure runs until August 10, 2026.